Clinical Trial Update: Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating whether brain-derived neurotrophic factor can predict response to quetiapine XR in bipolar disorder over 16 weeks.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Quetiapine XR (quetiapine)

Snippet

Sponsor: Hospital de Clinicas de Porto Alegre | Conditions: BIPOLAR DISORDER | Phase 3 | Status: UNKNOWN